Screener
Syndax Pharmaceuticals SNDX Royalty expense
Royalty expense at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Syndax Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RoyaltyExpense.
The source filing: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 4:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-197154
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Total operating expenses | 99,066 | 103,799 |
| Loss from operations | (34,202) | (83,757) |
| Other (expense) income, net: | ||
| Royalty interest expense | (11,846) | (8,049) |
| Other interest expense | — | (2) |
| Interest income | 3,561 | 7,183 |
| Other expense | (186) | (221) |
| Total other (expense) income, net | (8,471) | (1,089) |
Item 1: Financial Statements
FAQ
- What is Syndax Pharmaceuticals's royalty expense?
- Syndax Pharmaceuticals (SNDX) reported royalty expense of $11.85M in Q1 2026.
- How has Syndax Pharmaceuticals's royalty expense changed year-over-year?
- Syndax Pharmaceuticals's royalty expense increased by 47.2% year-over-year, from $8.05M to $11.85M.
- What does royalty expense mean?
- This metric captures the costs incurred for the right to use intellectual property, technology, or patents owned by third parties in the development or commercialization of product candidates. These expenses are typically calculated as a percentage of net sales or based on specific development milestones achieved. Monitoring this expense is critical for assessing the long-term margin impact of in-licensed assets on the company's bottom line.
Ask your AI about Syndax Pharmaceuticals's royalty expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude